Your session is about to expire
← Back to Search
LP-10 for Hemorrhagic Cystitis
Study Summary
This trial will assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus). 12 subjects will be enrolled and treated in a prospective and multi-center trial. 4 subjects will be allocated into each one of three groups.
- Hemorrhagic Cystitis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this trial available in many healthcare establishments within the state?
"Nine locations across the US are participating in this trial, including University of Arizona at Tucson, Emory University in Atlanta, and Vanderbilt University Medical Center near Nashville."
Are there opportunities to join this clinical experiment?
"As of today, the trial is open to participants. Clinicaltrials.gov records indicate that it was first posted on October 1st 2020, with a more recent update taking place in October 24th 2022."
Has the LP-10 drug been given official sanction by the FDA?
"LP-10 has been deemed to have an estimated safety rating of 2 as it is currently in Phase 2 trials, meaning there exists evidence of its security but not yet enough data on efficacy."
What is the total sample size for this clinical trial?
"The sponsor of the trial, Lipella Pharmaceuticals, Inc., requires 12 patients that meet their criteria to participate in this medical investigation. Two locations where it is being carried out are at University of Arizona located in Tucson and Emory University found in Atlanta."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger